Valuation: OLIPASS Corporation

Market Cap 26.53B 19.46M 17.45M 15.95M 14.56M 27.43M 1.83B 28.29M 192M 76.65M 976M 73.03M 71.46M 3.08B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.91M 13.37M 12.22M 11.16M 21.02M 1.4B 21.69M 147M 58.75M 748M 55.97M 54.77M 2.36B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
23,750
5 years 1,568
Extreme 1568
102,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-93.56% 9.88M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average -0.38%-2.20%+44.27%+158.03% 40.67B
Weighted average by Cap. +0.65%+3.07%+49.90%+165.87%

Financials

2021 2022
Net sales 852M 625K 560K 512K 467K 881K 58.72M 908K 6.17M 2.46M 31.33M 2.34M 2.29M 98.9M 2.3B 1.68M 1.51M 1.38M 1.26M 2.37M 158M 2.45M 16.64M 6.63M 84.45M 6.32M 6.18M 267M
Net income -25.13B -18.43M -16.53M -15.11M -13.79M -25.98M -1.73B -26.8M -182M -72.61M -924M -69.18M -67.7M -2.92B -24.17B -17.72M -15.9M -14.53M -13.26M -24.98M -1.67B -25.77M -175M -69.82M -889M -66.52M -65.1M -2.81B
Net Debt -18.29B -13.41M -12.03M -10.99M -10.04M -18.91M -1.26B -19.5M -133M -52.84M -673M -50.34M -49.26M -2.12B -6.2B -4.54M -4.07M -3.72M -3.4M -6.4M -427M -6.61M -44.88M -17.9M -228M -17.05M -16.69M -719M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock